Kiyoyuki Furuse
Osaka City University
150 Papers
1.5K Citations
Kiyoyuki Furuse is an academic researcher from Osaka City University. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 36, co-authored 150 publications.
Chat about Author
Papers
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer
Masaaki Kawahara,Kiyoyuki Furuse,Yoshihiko Segawa,Kozo Yoshimori,Kaoru Matsui,Shouji Kudoh,Kouichi Hasegawa,Hisanobu Niitani +7 more
TL;DR: S-1 was considered to be an active single agent against NSCLC and further study of S-1 with other active agents is warranted.
Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax
Keiji Iuchi,Akihiko Ichimiya,Akinori Akashi,Takatoshi Mizuta,Yong-Eun Lee,Hirohito Tada,Takashi Mori,Kenji Sawamura,Yong-Sik Lee,Kiyoyuki Furuse,Satoru Yamamoto,Katsuyuki Aozasa +11 more
TL;DR: In this article, a review of the literature showed that malignant lymphomas of this type have been reported exclusively from Japan but never from Western countries, thus, they cannot be found in most Western countries.
194
Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
S. Kudoh,Y. Fujiwara,Y. Takada,H Yamamoto,A Kinoshita,Yutaka Ariyoshi,Kiyoyuki Furuse,Masahiro Fukuoka +7 more
TL;DR: This is a new active regimen for SCLC, especially ED-SclC, with acceptable toxicity, and a phase III study that compares CPT-11/cisplatin with etoposide/cISplatin forED-SCLC is now being conducted.
176
Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer : A Japanese cooperative study
TL;DR: Docetaxel 60 mg/m2 showed significant activity in advanced NSCLC, with a low incidence of hypersensitivity or peripheral edema, and further investigation of this agent in NSCLc is warranted, especially in combination with other active drugs.
143
Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation
Masaaki Kawahara,S Ushijima,T. Kamimori,Kodama N,M Ogawara,Kaoru Matsui,N Masuda,M Takada,T Sobue,Kiyoyuki Furuse +9 more
TL;DR: Patients with small-cell lung cancer who survive more than 2 years have a significantly increased risk of developing a second primary tumour and the cessation of cigarette smoking after successful therapy is associated with a significantly decreased risk of a secondPrimary tumour.
139